Trial · NCT07906678
Effects of Daily Magnesium Complex Supplementation on Body Composition in University Students
NCT07906678, Not applicable, Not yet recruiting, Noakhali Science and Technology University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Daily Magnesium Complex Supplementation on Body Composition in University Students. Trials, record NCT07906678. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07906678
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Daily Magnesium Complex Supplementation on Body Composition in University Students
- NCT number
- NCT07906678
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Noakhali Science and Technology University
- Conditions
- Body Composition Changes, Muscle Mass, Body Fat Percentage
- Interventions
- Triple Magnesium Complex, Microcrystalline Cellulose Placebo
- First posted
- 2026-10-30
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Muscle mass | Baseline assessment on November 15, 2026, before initiation of the intervention, and post-intervention assessment on January 10, 2027, after completion of the 8-week intervention. | Muscle mass will be assessed at baseline and immediately after completion of the 8-week intervention using a calibrated TANITA SC-240 bioelectrical impedance analyzer. Change in muscle mass will be calculated for each participant by subtracting baseline muscle mass from Week 8 muscle mass. The change will be compared between the magnesium complex and placebo groups to evaluate the effect of daily magnesium complex supplementation on muscle mass in healthy young adults. Muscle mass will be expressed in kilograms (kg). |
| Primary | Body composition | Baseline assessment on November 15, 2026, before initiation of the intervention, and post-intervention assessment on January 10, 2027, after completion of the 8-week intervention. | Body fat percentage will be assessed at baseline and immediately after completion of the 8-week intervention using a calibrated TANITA SC-240 bioelectrical impedance analyzer. Change in body fat percentage will be calculated for each participant by subtracting the baseline body fat percentage from the Week 8 body fat percentage. The change will be compared between the magnesium complex and placebo groups to evaluate the effect of daily magnesium complex supplementation on body fat percentage in healthy young adults. Body fat percentage will be expressed as a percentage (%). |
| Secondary | Body weight | Baseline assessment on November 15, 2026, before initiation of the intervention, and post-intervention assessment on January 10, 2027, after completion of the 8-week intervention. | Body weight will be measured at baseline and immediately after completion of the 8-week intervention using standardized procedures. Change in body weight will be calculated for each participant by subtracting baseline body weight from body weight at Week 8. The change will be compared between the magnesium complex and placebo groups. Body weight will be expressed in kilograms (kg). |
| Secondary | Height | Baseline assessment on November 15, 2026, before initiation of the intervention, and post-intervention assessment on January 10, 2027, after completion of the 8-week intervention. | Height will be measured at baseline and immediately after completion of the 8-week intervention using standardized procedures. Change in height will be calculated by subtracting baseline height from height at Week 8. Height will be expressed in centimeters (cm). |
| Secondary | Body mass index (BMI) | Baseline assessment on November 15, 2026, before initiation of the intervention, and post-intervention assessment on January 10, 2027, after completion of the 8-week intervention. | Body mass index (BMI) will be assessed at baseline and immediately after completion of the 8-week intervention. BMI will be calculated by dividing body weight in kilograms by height in meters squared (kg/m²). Change in BMI will be calculated for each participant by subtracting baseline BMI from BMI at Week 8. The change will be compared between the magnesium complex and placebo groups. BMI will be expressed in kilograms per square meter (kg/m²). |
| Secondary | Waist circumference | Baseline assessment on November 15, 2026, before initiation of the intervention, and post-intervention assessment on January 10, 2027, after completion of the 8-week intervention. | Waist circumference will be measured at baseline and immediately after completion of the 8-week intervention using standardized procedures. Change in waist circumference will be calculated by subtracting baseline waist circumference from waist circumference at Week 8. The change will be compared between the magnesium complex and placebo groups. Waist circumference will be expressed in centimeters (cm). |
| Secondary | Hip circumference | Baseline assessment on November 15, 2026, before initiation of the intervention, and post-intervention assessment on January 10, 2027, after completion of the 8-week intervention. | Hip circumference will be measured at baseline and immediately after completion of the 8-week intervention using standardized procedures. Change in hip circumference will be calculated by subtracting baseline hip circumference from hip circumference at Week 8. The change will be compared between the magnesium complex and placebo groups. Hip circumference will be expressed in centimeters (cm). |
| Secondary | Waist-to-hip ratio | Baseline assessment on November 15, 2026, before initiation of the intervention, and post-intervention assessment on January 10, 2027, after completion of the 8-week intervention. | Waist-to-hip ratio will be calculated at baseline and immediately after completion of the 8-week intervention by dividing waist circumference by hip circumference. Change in waist-to-hip ratio will be calculated by subtracting the baseline ratio from the Week 8 ratio. The change will be compared between the magnesium complex and placebo groups. Waist-to-hip ratio is dimensionless and has no unit of measurement. |
| Secondary | Serum magnesium concentration | Baseline assessment on November 15, 2026, before initiation of the intervention, and post-intervention assessment on January 10, 2027, after completion of the 8-week intervention. | Serum magnesium concentration will be assessed at baseline and immediately after completion of the 8-week intervention. The change in serum magnesium concentration will be calculated for each participant by subtracting the baseline concentration from the Week 8 concentration. Changes will be compared between the magnesium complex and placebo groups to evaluate the effect of supplementation on serum magnesium levels. Serum magnesium concentration will be expressed in mg/dL. |
| Other | Age | At baseline (before randomization). | Age will be recorded in completed years at baseline and treated as a continuous covariate in the statistical analysis. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07906678
GET https://conductscience.org/api/trials/v1/NCT07906678/registered